Introduction
MicroRNAs (miRNAs) are a new class of naturally occurring small noncoding RNAs that regulate genes However, the role of miRNAs in gastric cancer remains largely unknown.
Gastric cancer ranks as the fourth most common cancer behind lung, breast and colorectal cancer, and the second leading cause of cancer-related death worldwide [7, 8] . Like other cancers, the development of gastric cancer is a multistep process with accumulation of genetic and epigenetic changes [9, 10] . Although a number of miRNAs that are associated with gastric cancer have been identified to date, the role of many of them in tumorigenesis and the underlying mechanism remain to be determined. Recently, we and others have identified some miRNAs deregulated in gastric cancer, such as downregulation of miR-141, miR-143, miR-145, miR-9 and miR-218 [11] [12] [13] [14] , and upregulation of miR-21, miR-150 and 106a [15] [16] [17] [18] . Nevertheless, until very recently, the function and regulation of these miRNAs in gastric cancer have hardly been explored.
Here, we provide evidence that miR-375 is one of the most frequently down-regulated miRNAs in gastric cancer tissues obtained from both gastric resection and gastroscopy. MiR-375 was able to significantly inhibit gastric cancer cell proliferation in vitro and in vivo and target Janus kinase 2 (JAK2) via its 3′-UTR region. Either inhibition of JAK2 activity by a small chemical inhibitor or downregulation of JAK2 by RNAi significantly suppressed the proliferation of gastric cancer cells. Ectopic expression of JAK2 was able to partially reverse the inhibition of cell proliferation caused by miR-375. Furthermore, miR-375 expression was inversely correlated with JAK2 protein level in gastric cancer. Thus, these data suggest that miR-375 may function as a tumor suppressor to influence the proliferation of gastric cancer cells by targeting the JAK2 oncogene. 
Results

MiR-375 is frequently downregulated in gastric cancer
To search miRNAs potentially involved in gastric tumorigenesis, we performed miRNA microarray profiling in six primary gastric tumors and their pair-matched nontumor tissues from patients undergoing gastric resection. A total of 15 miRNAs were detected to exhibit significantly differential expression in primary tumors compared to their nontumor controls by paired significance analysis of microarray (SAM) ( Figure 1A ). The expression pattern of four miRNAs (miR-21, miR-25, miR-106a and miR106b) was consistent with the previous profiling study, which was confirmed by other independent reports [12, 15, [17] [18] [19] [20] . Among them, miR-375 was shown to be the most significantly downregulated miRNA in stomach tumors. Quantitative real-time RT-PCR (qRT-PCR) analysis validated that miR-375 was greatly downregulated in about 94% of tumors (P < 0.01, 45 of 48 patients), with 3.94-fold reduction relative to their adjacent non-tumor tissues (Figure 1B and Supplementary information, Table  S1 ). To further investigate the expression of miR-375 in gastric cancer, we detected the expression of miR-375 in the age-and sex-matched samples from gastroscopy in a double-blind fashion and found that miR-375 was also significantly decreased in gastric cancer mucosa compared with non-tumor mucosa (P < 0.01) ( Figure 1C and Supplementary information, Table S2 ). To confirm the association between miR-375 expression and gastric cancer, we examined miR-375 expression in several gastric cancer cell lines using qRT-PCR. These data showed that miR-375 expression was substantially reduced in all the cell lines derived from gastric cancers with various differentiation degrees, compared with the nonmalignant gastric cell line GES-1 ( Figure 1D ) or non-tumor tissue (Supplementary information, Figure S1 ). Thus, these The xenografts with miR-375 overexpression were significantly smaller than the control xenografts. The mice were killed and the tumors were weighted 3 weeks after inoculation. Photograph of tumors developed in each group is shown (B). Tumors from each group were weighed immediately after removal. The average tumor weight is indicated as mean ± SE (C).
The cells were transfected with either miR-375 precursor or precursor-negative control oligonucleotides at different concentrations for various periods. The qRT-PCR analysis confirmed that the expression of mature miR-375 was significantly increased in cells transfected with miR-375 precursor compared with negative control (Supplementary information, Figure S2 ). Phase-contrast microscopy, MTT assays and direct cell counts showed that overexpression of miR-375 significantly inhibited the proliferation of both AGS and MGC-803 cells (Figure 2 and Supplementary information, Figure S3 ). Collectively, these results indicate that miR-375 may play a role in the proliferation of gastric cancer cells in vitro.
Increased miR-375 expression suppresses xenograft tumor formation
To further evaluate the potential effect of miR-375 on gastric cancer cell proliferation in vivo, MGC-803 cells with or without miR-375 overexpression were subcutaneously inoculated into both flanks of athymic nude mice. The mean volume of miR-375 overexpressing tumors was significantly smaller than that of the control, 10 days after inoculation ( Figure 3A ). At the end of the experimental period, the mean wet weight of tumors with miR-375 overexpression was significantly lower than that of the control ( Figure 3B and 3C). Thus, these data indicate that miR-375 may inhibit xenograft tumor formation of gastric cancer cells in vivo.
MiR-375 represses JAK2 protein expression through 3′-UTR
To investigate the mechanism of miR-375 function in gastric carcinogenesis, we employed miRanda, TargetScan and PicTar algorithms to search for putative human protein-coding gene targets of miR-375. The gene for JAK2, predicted by both TargetScan and PicTar, was further studied as a potential target ( Figure 4A ). Overexpression of miR-375 in AGS and MGC-803 cells greatly reduced the protein level of JAK2, whereas the level of JAK2 mRNA was not significantly affected ( Figure 4B and Supplementary information, Figure S4 ), suggesting that miR-375 may suppress JAK2 gene expression through translational repression. To test whether the predicted miR-375-binding sites in the 3′-UTR of JAK2 mRNA were responsible for its regulation, we cloned the 3′-UTR region of JAK2 downstream of a luciferase reporter gene (pMIR-JAK2), and co-transfected this vector together with miR-375 precursor or its negative control into AGS and MGC-803 cells. The luciferase activity of cells transfected with miR-375 precursor was significantly decreased compared with the negative control (P < 0.01) ( Figure 4C and 4D). Moreover, mutation of the putative miR-375-binding sites clearly abrogated the repression of luciferase activity caused by miR-375 overexpression ( Figure 4C and 4D ). These data suggest that miR-375 may inhibit JAK2 protein expression through 3′-UTR at the posttranscriptional level.
JAK2 is involved in the regulation of cell proliferation by miR-375
Because miR-375 inhibits gastric cancer cell proliferation and suppresses JAK2 protein expression, we are interested in examining whether miR-375 plays a role in the regulation of cell proliferation via JAK2 regulation. To examine the role of JAK2 in gastric cancer cell proliferation, we used tyrphostin AG490, a JAK2-specific inhibitor [21] , and found that AG490 significantly suppressed the proliferation of AGS and MGC-803 cells in a dose-and time-dependent manner ( Figure 5A and 5B), indicating a potential role of JAK2 in gastric cancer cell proliferation. To confirm this function of JAK2, we further employed vector-based RNAi technique to knockdown JAK2 and found that ectopic expression of pSilencer-JAK2 was able to effectively deplete JAK2, whereas the level of actin remained unchanged (Supple- mentary information, Figure S5A ). Meanwhile, depletion of endogenous JAK2 inhibited the proliferation of AGS and MGC-803 cells, which was consistent with the effect of miR-375 overexpression ( Figure 6 ). Furthermore, we examined whether JAK2 counteracted the inhibition of cell proliferation caused by miR-375 overexpression in gastric cancer cells. The vector of pCMV-JAK2 that contains only the JAK2 coding sequence was constructed for JAK2 expression without miR-375 targeting. The cells were co-transfected with miR-375 precursor and either pCMV-JAK2 or pCMV empty vector. The data clearly showed that ectopic expression of JAK2 effectively reversed the suppression of cell proliferation caused by miR-375 overexpression ( Figure 6 and Supplementary information, Figure S5B ). Taken together, these results are consistent with our hypothesis that miR-375 may inhibit gastric cancer cell proliferation potentially by regulating JAK2 expression.
The association of miR-375 expression with JAK2 protein levels in gastric cancer
As miR-375 was frequently down-regulated in gastric cancer and targeted JAK2 to inhibit cell proliferation, Each experiment was repeated at least three times, and each sample was assayed in triplicate. *P < 0.05, **P < 0.01 versus control (AG490, 0 µM).
Figure 6
The role of miR-375 in the regulation of gastric cancer cell proliferation. MiR-375 overexpression suppressed AGS (A) and MGC-803 (B) cell proliferation. The cells transfected with the indicated vectors or oligonucleotides were subjected with MTT assays. The rescue experiments for miR-375 overexpression were performed by ectopic expression of JAK2 without 3′-UTR in miR-375-treated cells. All the experiments were performed at least three times and a representative result is displayed as mean ± SD. *P < 0.05, **P < 0.01. we determined whether JAK2 protein level is associated with stomach cancer. The results revealed that JAK2 protein level was significantly increased in gastric cancer samples compared with their non-tumor counterparts (P < 0.05; Figure 7A ). To assess the clinical relevance of these findings, we correlated JAK2 level with miR-375 expression in the same patients. As shown in Figure  7B , when the relative expression levels of JAK2 (tumor/ normal) were plotted against that of miR-375 (tumor/ normal) in each patient, a significant inverse correlation was found (P < 0.05; r = −0.41). These data indicate that miR-375 down-regulation may be associated with the increase of JAK2 protein levels in gastric cancer.
Discussion
Although miRNA signatures for stomach cancer have been established, elucidation of the role of deregulated miRNAs in gastric carcinogenesis remains in the early stage of development. The data presented here showed a role of miR-375 in gastric cancer. MiR-375 is predominantly expressed in pancreatic islet, where it has been reported to regulate insulin secretion and gene expression by targeting myotrophin and 3′-phosphoinositidedependent protein kinase-1, respectively [22, 23] . MiR-375 gene knockout mice revealed that miR-375 is not only required for normal glucose homeostasis but also influences pancreatic α-and β-cell mass [24] . Inhibition of miR-375 maturation with morpholinos in zebrafish has revealed an essential role for miR-375 in the formation of insulin-secreting pancreatic islet [25] . By far, functional studies of miR-375 appear to be restricted to the regulation of pancreas. Here, we found that miR-375 was under-expressed in more than 90% of stomach cancer samples compared with their nontumor counterparts obtained from patients undergoing gastric resection, which was confirmed by the data from gastroscopy. MiR-375 was shown to inhibit gastric cancer cell proliferation partially by targeting JAK2. Moreover, miR-375 expression was inversely correlated with JAK2 protein level in gastric cancer. These findings indicate that miR-375 may function as tumor suppressor to influence gastric caner cell proliferation potentially by down-regulating JAK2 expression.
Until very recently, miR-375 has been found to be deregulated in some malignancies, including live tumor with β-catenin mutation, head and neck squamous cell carcinoma and pancreatic adenocarcinomas [26] [27] [28] [29] , whereas little is known about the molecular targets of miR-375 in these cancer. To our knowledge, JAK2 may be the first identified target gene that is involved in the regulation of carcinogenesis by miR-375.
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway mediates signaling by many cytokines, which is required for cell proliferation, survival and differentiation [30] . JAK2 is a member of the Janus family of cytoplasmic non-receptor tyrosine kinases, which also includes JAK1, JAK3 and TYK2 [31] . The V617F mutation of JAK2 is detected in many patients with polycythemia vera, essential thrombocythemia and primary myelofibrosis, resulting in activation of its tyrosine kinase activity, phosphorylation of STATs and expression of target genes [32] [33] [34] [35] . However, little is known about the role of JAK2 in solid tumors, especially in gastric cancer. A recent report failed to detect JAK2 mutation in gastric cancer [36] . Here, for the first time, we provide evidence that upregulation of JAK2 is associated with gastric cancer. Furthermore, down-regulation of JAK2 by either miR-375 overexpression or RNAi and inhibition of JAK2 activity by small molecule inhibitor were found to significantly suppress the proliferation of gastric cancer cells. These data suggest that JAK2 may play a role in gastric carcinogenesis.
Targeting JAK2 has emerged as an attractive strategy of novel drug development because it is mutated in many patients with myeloproliferative disorders [31, 37] . Most of the JAK2-directed drug discovery efforts are in early/ mid-stage of clinical development or are yet to reach the clinic. Of these small molecule inhibitors, lestaurtinib and INCB-18424 are currently being evaluated in phase II clinical trials [37] . Thus, it will be very interesting to evaluate the effectiveness of these molecules in the treatment of gastric cancer.
Additionally, identification of miR-375 downregulation in most gastric cancers may provide a new therapeutic opportunity. Studies regarding therapeutic utilization of miRNAs yielded encouraging results. The development of modified miRNA molecules with longer in vivo half-life and higher efficiency, such as the locked nucleic acid-modified oligonucleotides and the antisense oligonucleotides termed 'antagomirs', has produced favorable antitumor outcomes in experimental models [36, 38] . Enforced expression of miR-375 in gastric cancer by transfection of synthetic miR-375 oligonucleotides, infection of miR-375-carrying viruses or other approaches to increase endogenous miR-375, will be clearly needed for further studies.
Materials and Methods
Samples
Pair-matched tumorous and adjacent nontumorous gastric tissues from 48 patients undergoing resection for gastric cancer were obtained from Sir Run Run Shaw Hospital, Zhejiang University School of Medicine (Hangzhou, China). Written informed consent was obtained before collection. Non-tumor samples from the macroscopic tumor margin were isolated at the same time and used as the matched adjacent non-neoplastic tissues. All the samples were divided into two parts. One part was immediately snap frozen and stored in liquid nitrogen until RNA extraction. Another part was stored in formalin for pathology analysis. The histopathological investigations including hematoxylin and eosin staining were performed by two professional pathologists independently. Other clinical data were obtained from medical records within Sir Run Run Shaw Hospital, China. The clinicopathological characteristics Table S1 . Gastric mucosa samples including 17 nonmalignant mucosa and 17 malignant mucosa that were obtained from gastroscopy were also stored in liquid nitrogen until use. The clinical characteristics of these patients are reviewed in Supplementary information, Table S2 .
RNA extraction
Total RNA from tissue samples and cell lines was extracted using the mirVana miRNA Isolation Kit (Ambion, TX, USA) following the manufacture's protocol. RNA concentrations and quality were determined with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, DE, USA) and gel analysis.
miRNA microarray
Microarray analysis was performed on 5 µg of total RNA from histologically confirmed gastric cancers and adjacent normal tissues from the same patient, and was carried out using the µParaflo microfluidic technology according to the manufacturer's protocol (LC Sciences, TX, USA). Hybridization was performed overnight on a microfluidic chip. On the microfluidic chip, each detection probe consisted of a chemically modified nucleotide-coding segment complementary to target miRNA and a spacer segment of polyethylene glycol to extend the coding segment away from the substrate. The array covers all miRNA transcripts available in the Sanger miRBase database (release 10). Post-hybridization, detection used fluorescence labeling with tag-specific Cy3 and Cy5 dyes. Hybridization images were collected using a GenePix 4000B laser scanner (Molecular Device, CA, USA) and digitized using Array-Pro image analysis software (Media Cybernetics, MD, USA). The data were analyzed by first subtracting the background and then normalizing the signals to balance the intensities of the Cy3 and Cy5-labeled transcripts so that differential expression ratios can be calculated. The ratio of the two sets of detected signals (log 2 (cancer/normal)) and P-values of the t-test were calculated; differentially detected signals were those with a P-value less than 0.05. Deregulated miRNAs were divided into high or low signal using a signal intensity value of 500 normalized signal units.
Construction of plasmids
To produce pMIR-JAK2 plasmid, human JAK2 3′-UTR amplified by RT-PCR using the primers 5′-AAG AAA TGA CCT TCA TTC TGA GA-3′ and 5′-GTT ATG AAT TTT CTA CTG GCA TTC-3′ was cloned into pMIR-REPORT vector (Ambion). The mutation on miR-375-binding sites in human JAK2 3′-UTR was also generated by overlap PCR, as previously described [39] . For ectopic expression of FLAG-tagged JAK2, human JAK2 with coding region was cloned into pCMV-Tag 2C vector. To deplete endogenous JAK2 by RNAi, the oligo containing complementary hairpin sequences were synthesized and cloned into pSilencer 4.1-CMV neo vector (Ambion). The targeting sequence of JAK2 gene is 5′-AAC TCT ATC AGC TAC AAG ACA-3′, corresponding to the region 604-624 relative to the first nucleotide of the start codon. A circular pSilencer 4.1-CMV neo vector that expresses a hairpin siRNA with limited homology to any known sequence was used as a negative control. To construct the plasmid that expresses miR-375 in mammalian cells, the paired oligonucleotides based on the primary sequence of has-miR-375 and its flanking regions were cloned into mammalian expression vector pEGFP-C1 (Clontech, CA, USA). All of these constructs were confirmed by sequencing.
Cell culture
The biological characteristics and source of gastric cancer cell lines were summarized in our previous report [9] . The nonmalignant gastric cell line GES-1 was purchased from the Beijing Institute for Cancer Research (Beijing, China). These cells were maintained at 37 °C in an atmosphere of 5% CO 2 in RPMI-1640 (MGC-803, BGC-823, SGC-7901), DMEM (GES-1, HGC-27) or F12 (AGS) medium supplemented with 10% fetal bovine serum, penicillin and streptomycin (Gibco BRL, NY, USA) in 25-ml culture flasks.
Real-time PCR analysis
The expression of mature miRNAs was assayed using the Taqman MicroRNA Assays (Applied Biosystems, CA, USA) with specific primers for hsa-miR-375 (P/N: 4373151, Applied Biosystems) on tissue samples and cell lines. Reverse transcription reaction was carried out starting from 10 ng of total RNA using the looped primers. Real-time PCR was performed using the standard Taqman MicroRNA assays protocol on ABI7500 real-time PCR detection system. The ∆∆Ct method for relative quantization was used to determine miRNA expression. The Ct is the fractional cycle number at which the fluorescence of each sample passes the fixed threshold. The ΔCt was calculated by subtracting the Ct of snRNA U6 (RNU6B, P/N: 4373381, Applied Biosystems) from the Ct of the miRNA of interest. The ∆∆Ct was calculated by subtracting the ∆Ct of the reference sample (paired nontumorous tissue for surgical samples, normal tissues and GES-1 cell for five gastric cancer cell lines) from the ΔCt of each sample. Fold change was determined as 2 −∆∆Ct and miR-375 expression in endoscopic samples was also normalized to snRNA U6 using the 2 −∆Ct method.
Cell proliferation assay
To determine the effect of miR-375 on proliferation of gastric cancer cell lines, 4 × 10 3 cells were transfected with Pre-miR miR-375 precursor molecule (miR-375 precursor), Pre-miR miRNA precursor molecules' negative control no. 1 (negative control) using siPORT amine transfection agent (Ambion) or with mock control following manufacturer's protocol in 96-well plate. MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazoliumbromide) assay was performed at 24 h, 48 h and 72 h post transfection. The absorbance of the samples was measured with a spectrophotometer reader at 490 nm. Each assay was performed in triplicate and repeated three times independently.
Xenograft tumor model
Animal experiments were conducted in accordance with the Guide for the Care and Use of Animals for research purposes, and were approved by the Committee of Animal Ethics, Zhejiang University. Female athymic nude (nu/nu) mice (3-4 weeks old) were purchased from Shanghai Laboratory Animal Co Ltd (SLAC, Shanghai, China). The mice were bred and maintained under specific pathogen-free conditions in the Animal Facility, Zhejiang University. MGC-803 cells (5 × 10 6 ) transfected with either the vector overexpressing miR-375 or the control vector were inoculated subcutaneously into the left and right flanks of nude mice, respectively. The volume of the implanted tumor was measured at every 2 days with a vernier caliper, using the formula: V = L×W where V, volume (mm 3 ); L, biggest diameter (mm); W, smallest diameter (mm). The mice were killed and the tumors were weighd 3 weeks after inoculation.
Luciferase activity assay
In total, 40 000 cells were seeded in 24-well plates 24 h prior to transfection. Cells were cotransfected with 0.1 µg of either pMIR-JAK2 or pMIR-REPORT together with 40 nM of miR-375 precursor molecule or 40 nM of negative control no. 1 using siPORT amine transfection agent (Ambion) following manufacturer's protocol. The pRL-TK vector (Promega, WI, USA) containing Renilla luciferase was also cotransfected as a reference control. Firefly and Renilla luciferase activities were measured by using dualluciferase reporter assay (Promega) 24 h after transfection. Firefly luciferase activity was normalized to Renilla luciferase activity.
Western blotting
Western blotting analyses were performed as described previously [40] . In brief, the cells transfected with the indicated vectors or chemicals were subjected to western blotting with anti-JAK2 (Cell signaling, MA, USA) and actin (Santa Cruz Biotechnology, CA, USA) antibodies, respectively. Actin was used as a loading control.
Statistical analysis
Differential expressions of miRNA in surgical samples were determined by testing the null hypothesis that the mean of log2-transformed values of fold change was equal to 0 by one-sample t-test. Student's t-test was applied to determine the differences between sample means obtained from at least three experiments. Relationships between miR-375 and JAK2 expression were explored by Pearson's correlation coefficient, which is a technique for measuring the strength of the association between two quantitative, continuous variables. The Pearson's correlation coeffcient (R) may take any value from −1 to +1. The nearer the absolute value of R is to 1, the higher the strength of association between the variables. P < 0.05 was considered to be statistically significant. Statistical analyses were performed with SPSS software (version 13).
